Edwards Lifesciences Corporation

$89.79

+0.01%

2026-09-04 12:17:00 EDT+$0.01

Salud

Médico - Dispositivos

NYSE

Negociación activa

Edwards Lifesciences Corporation es una empresa global de tecnología médica que se especializa en productos y tecnologías sofisticados para enfermedades del corazón ...

Evolución del precio de EW

$89.79

+0.01%+$0.01

Máximo—

Mínimo—

Máx. 52s-6.8%

Vol. rel.—

Intervalo

Rango6.5h

Volumen—SMA5SMA10

—

Edwards Lifesciences Corporation, headquartered in Irvine, California, is a leading global medical technology company focused on structural heart disease and critical care monitoring. Founded in 1958 by Miles 'Lowell' Edwards, the company has a rich history of innovation, starting with the development of the first commercially available artificial heart valve. ...Edwards Lifesciences Corporation, headquartered in Irvine, California, is a leading global medical technology company focused on structural heart disease and critical care monitoring. Founded in 1958 by Miles 'Lowell' Edwards, the company has a rich history of innovation, starting with the development of the first commercially available artificial heart valve. Today, Edwards is a pioneer in minimally invasive transcatheter heart valve replacement and repair, offering products like the SAPIEN platform for aortic valves and the PASCAL and Cardioband systems for mitral and tricuspid valve pathologies. Their surgical portfolio includes the INSPIRIS RESILIA aortic valve and the KONECT RESILIA valved conduit, alongside specialized tools like the HARPOON system for beating-heart mitral valve repair. In critical care, Edwards provides advanced hemodynamic monitoring systems and software such as the Acumen Hypotension Prediction Index, which helps clinicians anticipate and manage patient blood pressure risks. The company operates globally across the US, Europe, Japan, and other international markets, serving healthcare providers through both a direct sales force and distributor networks. With 16,000 employees, Edwards generated $6.5 billion in revenue for the trailing twelve months, exhibiting a gross profit margin of 78% and an operating margin of 28%. The company invests heavily in R&D (16.7% of revenue) to maintain its innovation edge. Financially, Edwards shows a strong balance sheet with a debt-to-equity ratio of just 0.066 and a current ratio of 4.52, reflecting robust liquidity. Its market capitalization stands at approximately $51.4 billion. Led by CEO Bernard J. Zovighian since May 2023, Edwards is committed to its mission of improving patient lives through breakthrough structural heart and critical care technologies, with a clear focus on expanding its transcatheter therapies and achieving worldwide adoption of its innovative products.ExpandirContraer

Fundación

1958

Empleados

16000

CEO

Bernard J. Zovighian

Nombre completo

Edwards Lifesciences Corporation

Sector

Salud

Industria

Médico - Dispositivos

ROE

9.69%

Capitalización

$51.75B

Ratio corriente

4.52

WACC

8.46%

ROIC

9.24%

Información de contacto

https://www.edwards.com

949 250 2500

One Edwards Way, Irvine, CA 92614

Métricas clave de EW

Instantánea

Último / TTM · 6 periodos

Capitalización

$51.75B

ROCE

14.8%

EV / EBITDA

32.14x

+1.0% YoY

Rendimiento FCF

2.8%

+0.1% YoY

Ciclo de conversión de efectivo

287.6d

Ratio corriente

4.52

Resumen rápido

TTM —

Positive CCC

Aspectos financieros de EW

Tendencia de rentabilidad

Último / TTM · 6 periodos

Margen bruto

78.0%

Margen neto

15.4%

PER

51.60x

n/d

Deuda / capital

0.07

n/d

Ratio corriente

4.52

Rendimiento del dividendo

0.0%

Comprensión

TTM —

La cobertura de intereses es débil

Calendario de EW

Próximamente

30 sept 2026En 26 días
Q3 FY2026 · Resultados estimados
BPA est. $0.74 · Ingresos $1.68B · 16 analistas
30 dic 2026
Q4 FY2026 · Resultados estimados
BPA est. $0.71 · Ingresos $1.70B · 15 analistas
31 dic 2026
FY2026 · Resultados anuales estimados
BPA est. $3.00 · Ingresos $6.77B · 16 analistas
30 mar 2027
Q1 FY2027 · Resultados estimados
BPA est. $0.84 · Ingresos $1.80B · 6 analistas

Historial reciente

4 ago 2026
Q2 FY2026 · Resultados publicados
BPA $0.42 · Ingresos $1.74B
Ver documento
6 may 2026
Q1 FY2026 · Resultados publicados
BPA $0.66 · Ingresos $1.65B
Ver documento
25 feb 2026
FY2025 · Resultados anuales
BPA $1.83 · Ingresos $6.07B
Ver documento
5 nov 2025
Q3 FY2025 · Resultados publicados
BPA $0.50 · Ingresos $1.55B
Ver documento
6 ago 2025
Q2 FY2025 · Resultados publicados
BPA $0.56 · Ingresos $1.53B
Ver documento
6 may 2025
Q1 FY2025 · Resultados publicados
BPA $0.61 · Ingresos $1.41B
Ver documento

Estados financieros de EW

Tendencia de 5 años (ingresos, beneficios, FCF)

Métrica	Último	InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo.	TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo.
IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores).	$6.1B	+11.5%	+5.6%
Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día.	$1.1B	-74.3%	-36.5%
Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión.	+78.1%	-1.7%	-0.8%
Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas).	+27.0%	+6.4%	-4.4%
Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas.	+17.7%	-76.9%	-39.8%
Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones.	$1.3B	+360.5%	+2872.5%
Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero.	+22.0%	+312.8%	+2725.4%
Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro.	6.8%	-2.5%	-2.5%
Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico.	3.72x	-11.0%	+2.3%
Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo.	$13.7B	+4.9%	+4.1%

Real vs estimado

A Dec 31Q Sep 30

Métrica	Anual (real vs estimado)	Sorpresa anual	Trimestral (real vs estimado)	Sorpresa trimestral
EPS Surprise	1.83 vs 2.60	-29.5%	0.42 vs 0.74	-43.1%
Revenue Surprise	$6.1B vs $6.0B	+0.4%	$1.7B vs $1.7B	+3.9%

Transacciones de insiders de EW

Compras (A)

Since Aug 11, 2026

Ventas (D)

Since Aug 11, 2026

Acciones mensuales compradas/vendidas con tendencia del precio de cierre (fuente diaria compartida)

Resumen de trading de insiders

Fecha	Ejecutivo	Cargo	Valor	Lado	Acciones	Precio
Aug 31, 2026	Dahl Andrew M.	officer: SVP, Corporate Controller	Common Stock	D	544	$91.06
Aug 28, 2026	Bruls Annette	officer: CVP, EMEACLA	Common Stock	D	2,644	$89.98
Aug 26, 2026	Chopra Daveen	officer: CVP, TMTT, Surgical & IHFM	Common Stock	A	31,800	$72.68
Aug 26, 2026	Chopra Daveen	officer: CVP, TMTT, Surgical & IHFM	Common Stock	D	1,154	$91.76
Aug 26, 2026	Chopra Daveen	officer: CVP, TMTT, Surgical & IHFM	Common Stock	D	30,646	$90.99

Transcripción de la llamada de resultados de EW

1 segmentos de transcripción

Q2 2026

Ponente desconocido

Operator : Greetings, and welcome to the Edwards Lifesciences Second Quarter 2026 Earnings Conference Call. As a reminder, this conference call is being recorded. It is now my pleasure to introduce Gerianne Sarte, Head of Investor Relations. Thank you. You may begin. Gerianne Sarte : Good afternoon, and thank you for joining us. With me on today's call is our CEO, Bernard Zovighian; and our CFO, Doretta Mistras. Also joining us for the Q&A portion of the call will be Dan Lippis, our Global Leader of TAVR; and Daveen Chopra, who has global responsibility for TMTT, Surgical and IHFM. After the close of regular trading, Edwards Lifesciences released second quarter 2026 financial results. During today's call, management will discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause these differences can be found in today's press release and Edwards' other SEC filings, all of which are available on the company's website at edwards.com. Unless otherwise noted, our commentary on sales growth refers to underlying sales growth, which is defined in the financial results press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during this call are also included in today's press release. Quarterly and full year growth rates refer to continuing operations. With that, I'll turn it over to Bernard for his comments. Bernard? Bernard Zovighian : Thank you, Gerianne, and welcome, everyone. Before we begin, I'd like to welcome Doretta to our first Edwards Life Sciences earnings call. Since joining in June, Doretta has quickly demonstrated her impact and valuable contribution as a member of the team, and we are pleased to have her leadership as we deliver on our patient-centered innovation strategy and our commitments to sustainable, distinguished performance. Let me begin with a high-level comment on our quarterly performance. We delivered stronger-than-expected second quarter sales growth of 12.5%. As Edwards continues to invest in new structural heart therapies and expand adoption globally, our results increasingly reflect the strength of our comprehensive portfolio with growth supported by multiple therapies across TAVR, mitral, tricuspid and surgical as well as meaningful contribution from each of our regions. Today, our company profile has evolved to include multiple strategic platforms across multiple regions that will support durable growth, giving us confidence in our target of …

Equipo directivo de EW

10 directivos

Nombre	Cargo	Remuneración	Género	Año de nacimiento	Estado
Bernard J. Zovighian	Chief Executive Officer & Director	USD 3,788,122	Male	1968	Active
Theodora Mistras	Corporate Vice President & Chief Financial Officer	USD 1,845,590	Female	1982	Active
Annette Maria Bruls	Corporate Vice President of EMEA, Canada, & Latin America	USD 1,627,873	Female	1971	Active
Donald E. Bobo Jr.	Corporate Vice President of Strategy & Corporate Development	USD 1,595,262	Male	1962	Active
Daveen Chopra	Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies	USD 1,555,892	Male	1979	Active
Joseph Nuzzolese	Corporate Vice President of Global Operations & Quality	—	Male	—	Active
Mark D. Peterson	Corporate Vice President & General Counsel	—	Male	1963	Active
Todd Brinton FACC	Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer	—	—	—	Active
Andrew Dahl	Principal Accounting Officer, Senior Vice President & Corporate Controller	—	Male	1978	Active
Snehashish Sarkar	Senior VP and Chief Information & Digital Officer	—	Male	1975	Active

Noticias recientes de EW

GuruFocus26/8/2026Neutral

Is EW Overvalued? DCF Says Worth $53

On August 26, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has seen a price performance of +12.4% over the past year

Defense World26/8/2026Neutral

Bank of Nova Scotia Takes Position in Edwards Lifesciences Corporation $EW

Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,417 shares of the medical research company's stock, valued at approximately $5,465,000. Several other hedge funds also recently made

Defense World23/8/2026Neutral

37,702 Shares in Edwards Lifesciences Corporation $EW Bought by EP Wealth Advisors LLC

EP Wealth Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 37,702 shares of the medical research company's stock, valued at approximately $3,410,000. Other institutional investors and hedge

Defense World22/8/2026Neutral

B. Metzler seel. Sohn & Co. AG Buys Shares of 41,753 Edwards Lifesciences Corporation $EW

B. Metzler seel. Sohn and Co. AG acquired a new position in Edwards Lifesciences Corporation (NYSE: EW) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,753 shares of the medical research company's stock, valued at approximately $3,777,000. Several other hedge

Defense World22/8/2026Neutral

Allworth Financial LP Takes Position in Edwards Lifesciences Corporation $EW

Allworth Financial LP bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 16,600 shares of the medical research company's stock, valued at approximately $1,502,000. A number of other hedge funds have also

Evolución del número de empleados de EW

Actual

16,000

Cambio

+1.27%

Mínimo

15,700

Máximo

19,800

Presentaciones recientes

Fecha del informe	Empleados	Tipo de formulario	Fecha de presentación	Archivo SEC
31 dic 2025	16,000	10-K	25 feb 2026	Ver
31 dic 2024	15,800	10-K	28 feb 2025	Ver
31 dic 2023	19,800	10-K	12 feb 2024	Ver
31 dic 2022	17,300	10-K	13 feb 2023	Ver
31 dic 2021	15,700	10-K	14 feb 2022	Ver

Acciones relacionadasMedical - Devices

Ver todas las acciones de EE. UU. →

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

Edwards Lifesciences Corporation